The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| 5 01 ACQUISITION CORP | COM CL A | 33836P105 | 3,640 | 365,126 | SH | SOLE | 365,126 | 0 | 0 | ||
| AKOUOS INC | COM | 00973J101 | 51,904 | 4,135,784 | SH | SOLE | 4,135,784 | 0 | 0 | ||
| ARVINAS INC | COM | 04335A105 | 30,800 | 400,000 | SH | SOLE | 400,000 | 0 | 0 | ||
| CABALETTA BIO INC | COM | 12674W109 | 25,665 | 2,984,263 | SH | SOLE | 2,984,263 | 0 | 0 | ||
| CIDARA THERAPEUTICS INC | COM | 171757107 | 4,053 | 2,006,511 | SH | SOLE | 2,006,511 | 0 | 0 | ||
| CRINETICS PHARMACEUTICALS IN | COM | 22663K107 | 25,679 | 1,362,286 | SH | SOLE | 1,362,286 | 0 | 0 | ||
| HOMOLOGY MEDICINES INC | COM | 438083107 | 32,976 | 4,535,919 | SH | SOLE | 4,535,919 | 0 | 0 | ||
| IDEAYA BIOSCIENCES INC | COM | 45166A102 | 37,741 | 1,798,066 | SH | SOLE | 1,798,066 | 0 | 0 | ||
| IMPEL NEUROPHARMA INC | COM | 45258K109 | 25,530 | 2,884,791 | SH | SOLE | 2,884,791 | 0 | 0 | ||
| JANUX THERAPEUTICS INC | COM | 47103J105 | 11,134 | 446,266 | SH | SOLE | 446,266 | 0 | 0 | ||
| SCPHARMACEUTICALS INC | COM | 810648105 | 23,410 | 3,831,474 | SH | SOLE | 3,831,474 | 0 | 0 | ||
| VOR BIOPHARMA INC | COM | 929033108 | 124,814 | 6,692,429 | SH | SOLE | 6,692,429 | 0 | 0 | ||